Natixis Allakos Inc. Transaction History

Natixis

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.6 - $6.14 $299,000 - $706,100	-115,000 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$5.08 - $9.81 $147,828 - $285,471	29,100 Added 33.88%	115,000 $656,000
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $190,374 - $2.49 Million	-22,266 Reduced 20.59%	85,900 $841,000
Q3 2021 Nov 12, 2021	BUY	$76.53 - $110.43 $476,399 - $687,426	6,225 Added 6.11%	108,166 $11.5 Million
Q2 2021 Aug 13, 2021	SELL	$85.37 - $114.1 $4.36 Million - $5.83 Million	-51,100 Reduced 33.39%	101,941 $8.7 Million
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $8.91 Million - $12.5 Million	81,200 Added 113.03%	153,041 $17.6 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $1.14 Million - $2.18 Million	14,329 Added 24.91%	71,841 $10.1 Million
Q3 2020 Nov 12, 2020	BUY	$66.43 - $90.99 $3.82 Million - $5.23 Million	57,512 New	57,512 $4.68 Million

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $24.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.